Discussion on drug toxicity and application of toxic durgs in rheumatic immune diseases in children from the perspective of "You Gu Wu Yun" in Huangdi Neijing

  • role: Corresponding author, First author通信作者, 第一作者
  • Affiliation:

    School of Pediatrics, Henan University of Chinese Medicine, Zhengzhou 450046, China

    The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450003, China

  • Email:dingying3236@ sina.com
  • Introduction:,西50湿西使222233981
DING Ying12*

ملخص

Rheumatic immune diseases in children are difficult to treat, frequently recur, and can seriously affect children’s physical and mental health. At present, treatment of rheumatic immune diseases mainly depends on hormones, biologicals and immunosuppressants. However, these drugs have nonnegligible side effects. Traditional Chinese medicine deems that the side effects of drugs belong to the category of drug "toxicity". Drugs that are toxic are called "toxicity" drugs, with regard to "toxicity" drugs, the theory of "You Gu Wu Yun" in Inner canon of Huangdi considers that although drugs are "toxic, " drugs are used for an explicit "reason, " so the disease itself receives the drug first, which are not harmful to the human body. Based on this theory, we propose "toxicity" drugs’ use principles that "toxicity" drugs are severe; therefore, drugs should not be used until the plight is urgent. "Toxicity" drugs should be stopped when the disease is mostly cured. The "effectiveness" and "toxicity" must be weighed to find a balance between the body and the drugs. Treatment ought to be adapted according to personal condition, because tolerance to "toxicity" drugs varies. Drugs must be used based on disease differentiation and syndrome differentiation, and toxicity must be reduced by compatibility. We also put forward the "toxicity" drugs’ use strategies of precising drugs’ use, taking measures to attenuate toxicity, improving the benefit/risk ratio, which are of great guiding significance to the safe use of drug in pediatric clinics.

مفهوم

You Gu Wu Yun;drug toxicity;toxicity drug;children;rheumatic immune disease

References

  1. [1].
    黄灿,何法静,杨潇,等.环磷酰胺所致小鼠肝损伤的动态变化[J].药学学报,2019,54(6):1062-1068.
  2. [2].
    鲍岩岩,毛鑫,高英杰,等.艾康片减轻环磷酰胺心脏毒性研究[J].新中医,2021,53(7):11-15.
  3. [3].
    陈中.雷公藤红素致心脏毒性的分子机制研究[D].南京:南京师范大学,2012.
  4. [4].
    管斯琪,何军琴,王景尚,等.雷公藤多苷对小鼠生殖毒性机制的转录组学研究[J].中国性科学,2021,30(11):1-5.
  5. [5].
    张成,韦嵩.双乌宣痹颗粒治疗急性期类风湿关节炎临床观察[J].中国中医急症,2014,23(10):1786-1787.
  6. [6].
    张倩.加味木防己汤联合甲氨蝶呤治疗类风湿关节炎急性发作期的疗效[J].临床合理用药杂志,2022,15(2):39-42.
  7. [7].
    谢政权,季兵,刘峰,等.加味木防己汤合甲氨蝶呤治疗类风湿关节炎急性发作期疗效观察[J].现代中西医结合杂志,2018,27(19):2148-2151.
  8. [8].
    王龙,徐闪闪,代彦林,等.雷公藤多苷片联合清热止血方对紫癜性肾炎患者的临床疗效[J].中成药,2021,43(4):914-918.
  9. [9].
    李季.不同剂量昆明山海棠配伍川断全蝎治疗活动期类风湿关节炎的观察[D].广州:广州中医药大学,2013.
  10. [10].
    王丽.附子复方不同增量方式治疗类风湿关节临床观察[D].成都:成都中医药大学,2013.
  11. [11].
    王爽,张贺峰,刘艳华.附子复方不同增量方式治疗类风湿关节炎的临床观察[J].中国卫生标准管理,2018,9(20):98-100.
  12. [12].
    丁樱,李雪军,张霞,等.雷公藤颗粒治疗儿童反复性过敏性紫癜的剂量探索[J].中医学报,2021,36(4):860-864.
  13. [13].
    赵明妹.糖皮质激素对风湿免疫病患者骨密度的影响分析[J].当代医学,2021,27(17):34-35.
  14. [14].
    宣亚男,邱富娟,李凯芹,等.狼疮方治疗热毒血瘀型系统性红斑狼疮疗效的回顾性分析及机制初探[J].广东医学,2022,43(4):441-446.
  15. [15].
    杨新方.益气养阴法治疗系统性红斑狼疮(气阴两虚证)临床疗效观察[D].成都:成都中医药大学,2017.
  16. [16].
    翟文生,李冰,杨濛,等.紫癜肾1号方联合雷公藤多苷治疗儿童紫癜性肾炎血尿加蛋白尿型35例临床观察[J].时珍国医国药,2018,29(1):131-133.
  17. [17].
    杨濛,翟文生,李冰,等.血尿2号方联合雷公藤多苷片治疗儿童单纯血尿型紫癜性肾炎62例临床观察[J].中国民族民间医药,2019,28(11):80-82.
  18. [18].
    吴莉.雷公藤多苷对以大量蛋白尿为主要表现的中度紫癜性肾炎患儿的疗效评价[D].杭州:浙江大学,2014.
  19. [19].
    宋玲玲,王君明,关月晨,等.基于传统散剂和炒炙法的雷公藤炮制减毒作用研究[J].中华中医药杂志,2021,36(10):6167-6171.
  20. [20].
    关月晨,王君明,宋玲玲,等.金钱草煎汤炒炙雷公藤的炮制减毒工艺研究[J].中国中药杂志,2021,46(5):1128-1133.
  21. [21].
    南丽红,郑燕芳,徐伟,等.不同炮制方法对雷公藤的急性毒性和抗炎作用的影响[J].时珍国医国药,2015,26(8):1900-1902.
  22. [22].
    代彦林,韩姗姗,丁樱,等.清热止血方联合雷公藤多苷治疗儿童紫癜性肾炎疗效及其对血清sFlt-1、vWF的影响[J].中国中医基础医学杂志,2022,28(8):1296-1299.

قراءة النص الكامل

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website